| DNA polymerase epsilon and delta variants drive mutagenesis in polypurine tracts in human tumors. | DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D, Tyryshkin K, Beach AK, Moore EA, Masoudi-Sobhanzadeh Y, Barbari SR, Rogozin IB, Shaitan KV, Panchenko AR, Shcherbakova PV., Free PMC Article | 06/21/2024 |
| Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity. | Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM, Demidova EV, Ringenbach S, Faezov B, Andrake M, Gandhi A, Mur P, Viana-Errasti J, Xiu J, Swensen J, Valle L, Dunbrack RL Jr, Hall MJ, Arora S., Free PMC Article | 06/21/2024 |
| Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants. | Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
Selves J, de Castro E Gloria H, Brunac AC, Saffi J, Guimbaud R, Brousset P, Hoffmann JS., Free PMC Article | 04/22/2024 |
| Cervical Cytology Preserves Histologically Detected Surface Epithelial Slackening, Unique to the POLE Mutation-subtype in Endometrial Cancer. | Cervical Cytology Preserves Histologically Detected Surface Epithelial Slackening, Unique to the POLE Mutation-subtype in Endometrial Cancer.
Kitazono I, Akahane T, Yokoyama S, Kubota E, Nishida-Kirita Y, Noguchi H, Murakami M, Yanazume S, Kobayashi H, Tanimoto A., Free PMC Article | 03/29/2024 |
| Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases epsilon and delta in glioma families. | Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families.
Weber CAM, Krönke N, Volk V, Auber B, Förster A, Trost D, Geffers R, Esmaeilzadeh M, Lalk M, Nabavi A, Samii A, Krauss JK, Feuerhake F, Hartmann C, Wiese B, Brand F, Weber RG., Free PMC Article | 03/13/2024 |
| The P286R mutation of DNA polymerase epsilon activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway. | The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
Tang M, Yin S, Zeng H, Huang A, Huang Y, Hu Z, Shah AR, Zhang S, Li H, Chen G., Free PMC Article | 02/1/2024 |
| Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial Cancer. | Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial Cancer.
Zheng S, Donnelly ED, Strauss JB., Free PMC Article | 01/29/2024 |
| Cytopathological features associated with POLE mutation in endometrial cancer. | Cytopathological features associated with POLE mutation in endometrial cancer.
Yanazume S, Iwakiri K, Kobayashi Y, Kitazono I, Akahane T, Mizuno M, Togami S, Tanimoto A, Kobayashi H. | 08/11/2023 |
| A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma. | A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.
Devereaux KA, Steiner DF, Ho C, Gomez AJ, Gilks B, Longacre TA, Zehnder JL, Howitt BE, Suarez CJ. | 11/5/2022 |
| An in silico analysis of the impact of POLE mutations on cladribine docking. | An in silico analysis of the impact of POLE mutations on cladribine docking.
Loganathan L, Al-Haidose A, Ganesh Kumar A, Sujatha LB, Carlus FH, Alharbi A, Alhyassat S, Muthusamy K, Carlus SJ, Abdallah AM. | 11/5/2022 |
| The iron-sulfur cluster is essential for DNA binding by human DNA polymerase epsilon. | The iron-sulfur cluster is essential for DNA binding by human DNA polymerase ε.
Lisova AE, Baranovskiy AG, Morstadt LM, Babayeva ND, Stepchenkova EI, Tahirov TH., Free PMC Article | 10/29/2022 |
| Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. | Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Ma X, Riaz N, Samstein RM, Lee M, Makarov V, Valero C, Chowell D, Kuo F, Hoen D, Fitzgerald CWR, Jiang H, Alektiar J, Alban TJ, Juric I, Parthasarathy PB, Zhao Y, Sabio EY, Verma R, Srivastava RM, Vuong L, Yang W, Zhang X, Wang J, Chu LK, Wang SL, Kelly DW, Pei X, Chen J, Yaeger R, Zamarin D, Zehir A, Gönen M, Morris LGT, Chan TA., Free PMC Article | 07/23/2022 |
| POLE/POLD1 mutation and tumor immunotherapy. | POLE/POLD1 mutation and tumor immunotherapy.
Ma X, Dong L, Liu X, Ou K, Yang L., Free PMC Article | 07/23/2022 |
| Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. | Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation.
Wen L, Chen Z, Ji X, Fong WP, Shao Q, Ren C, Cai Y, Li B, Yuan Y, Wang D, Li Y., Free PMC Article | 07/16/2022 |
| Efficient discrimination against RNA-containing primers by human DNA polymerase epsilon. | Efficient discrimination against RNA-containing primers by human DNA polymerase ε.
Lisova AE, Baranovskiy AG, Morstadt LM, Babayeva ND, Tahirov TH., Free PMC Article | 06/25/2022 |
| Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study. | Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
Yu S, Sun Z, Zong L, Yan J, Yu M, Chen J, Lu Z., Free PMC Article | 05/7/2022 |
| PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation. | PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.
Schenck K, Masetti M, Pfarr N, Lorenzen S. | 04/16/2022 |
| Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. | Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.
Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA., Free PMC Article | 04/9/2022 |
| Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer. | Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer.
Keshinro A, Vanderbilt C, Kim JK, Firat C, Chen CT, Yaeger R, Ganesh K, Segal NH, Gonen M, Shia J, Stadler Z, Weiser MR., Free PMC Article | 03/26/2022 |
| Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors. | Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors.
Hwang HS, Kim D, Choi J., Free PMC Article | 03/19/2022 |
| The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. | The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
Jumaah AS, Al-Haddad HS, McAllister KA, Yasseen AA., Free PMC Article | 03/5/2022 |
| POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. | POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX, Wang ZX, Yuan SQ, Jiang TJ, Huang YS, Xu RH, Wang F, Zhao Q., Free PMC Article | 02/12/2022 |
| Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. | Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations.
Kawai T, Nyuya A, Mori Y, Tanaka T, Tanioka H, Yasui K, Toshima T, Taniguchi F, Shigeyasu K, Umeda Y, Fujiwara T, Okawaki M, Yamaguchi Y, Goel A, Nagasaka T., Free PMC Article | 01/29/2022 |
| Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma. | Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma.
Raffone A, Travaglino A, Raimondo D, Boccellino MP, Maletta M, Borghese G, Casadio P, Insabato L, Mollo A, Zullo F, Seracchioli R. | 12/25/2021 |
| Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan. | Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan.
Monsur M, Yamaguchi M, Tashiro H, Yoshinobu K, Saito F, Erdenebaatar C, Li C, Iwagoi Y, Ohba T, Iyama KI, Katabuchi H. | 12/18/2021 |